… of driver mutation in non-small-cell lung cancer. Alterations in Kirsten … in non-small-cell lung
cancer, highlighting the importance of … Mutations leading to excessive EGFR activity are most …

… EGFR T790M resistance mutations. In the phase III FLAURA study of osimertinib versus
standard-of-care (SoC) EGFR… cell lung cancer (NSCLC) harboring EGFR sensitizing mutations […

… and Korea) with newly diagnosed NSCLC and EGFR mutation (exon 19 deletion or exon 21
… Randomization was stratified by race and EGFR mutation type. An ad hoc updated analysis …

… 7 trial compared afatinib with gefitinib as a first-line treatment in patients with advanced
NSCLC harboring common EGFR mutations (Del19 and the L858R point mutation) [8]. Although …

… L858R mutation later in tumor evolution consistent with previous reports inherited susceptibility
of lung cancer and heterogeneous development of sensitizing EGFR mutations in these …

… There is a need for a broader EGFR panel beyond looking at the EGFR T790M mutation, so
… a qPCR-based EGFR mutation panel that also includes the activating EGFR mutations. The …

… with HER3-DXd and EGFR-TKI in EGFR-mutated NSCLC that is currently … EGFR-mutated
NSCLC tumors, not only with regard to an acquired resistance to EGFR-TKI but also in EGFR-…

… lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with
EGFR tyrosine kinase inhibitors (EGFR … T790M or other acquired mutations are sensitive to …

… mutation burden is considered predictive of a benefit for checkpoint inhibition and EGFR-mutated
lung cancer was shown to have low mutation … presence of EGFR mutations seems to …

… Erlotinib versus standard chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-…